多嚢胞性卵巣症候群(Polycystic Ovarian Syndrome)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Polycystic Ovarian Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Polycystic Ovarian Syndrome – Overview 7
Pipeline Products for Polycystic Ovarian Syndrome – Comparative Analysis 8
Polycystic Ovarian Syndrome – Therapeutics under Development by Companies 9
Polycystic Ovarian Syndrome – Therapeutics under Investigation by Universities/Institutes 10
Polycystic Ovarian Syndrome – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Polycystic Ovarian Syndrome – Products under Development by Companies 14
Polycystic Ovarian Syndrome – Products under Investigation by Universities/Institutes 15
Polycystic Ovarian Syndrome – Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Crinetics Pharmaceuticals, Inc. 17
EffRx Pharmaceuticals S.A. 18
Euroscreen S.A. 19
Merck KGaA 20
Neurocrine Biosciences, Inc. 21
Polycystic Ovarian Syndrome – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AZD-4901 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
choriogonadotropin alfa – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ESN-364 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
metformin hydrochloride – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Polycystic Ovarian Syndrome – Recent Pipeline Updates 40
Polycystic Ovarian Syndrome – Dormant Projects 41
Polycystic Ovarian Syndrome – Product Development Milestones 42
Featured News & Press Releases 42
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 42
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 43
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46